News for IN8bio, Inc. (INAB)

IN8bio (INAB) has reported promising progress in its Phase 1 trial of INB-200, treating newly-diagnosed glioblastoma multiforme (GBM). A noteworthy patient, kno

IN8bio's (INAB) INB-200 therapy achieved a 4-year remission for a patient with grade 4 IDH-mutant glioma. INB-200 demonstrated a median progression-free

IN8bio, Inc. (INAB) experienced a trading halt at 19:50 EDT as the market anticipates an important announcement from the company. The halt in trading indicates

IN8bio, Inc. (INAB) has unveiled encouraging long-term clinical data from its Phase 1 trial of INB-200, which is being tested on patients newly diagnosed with g

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observ

IN8bio (INAB) has introduced compelling preclinical findings for its INB-619 program at the 2025 ASGCT Annual Meeting. The research demonstrated that INB-619 ef

IN8bio (INAB) recently unveiled promising advancements in its gammadelta T cell manufacturing technique. Presented at the International Society for Cell & Gene

Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demons

**media[618076]**

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ( INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapi

IN8bio (INAB) has released encouraging new preclinical findings from its innovative gamma delta T cell engager platform. Set to be presented at the 2025 America

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ( INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapi

Net Loss: Reported a net loss of $6.2 million, or $0.08 per share, for Q4 2024, aligning with the estimated EPS of -0.08.Research and Development Expenses: R&D

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100%

**media[566089]**

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next

**media[555772]**

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ( INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ( INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell